‼️ More Biopsy ≠ Better Care
We perform ~1.59M breast biopsies each year in the U.S., and 65–75% are benign. That’s roughly 1.0–1.2M invasive procedures that deliver anxiety, complications, and delays without cancer. At an average $1,938 per biopsy, that’s about $3.07B in annual spend before treatment even starts.
👉 The upstream failure is image clarity.
Low-quality ultrasound pushes borderline cases to biopsy “just to be safe.” PONS upgrades standard ultrasound with device-agnostic AI: higher tissue contrast, reduced noise, and digital contrast (no injections) that reveals subtle morphology on the first pass. Clinicians receive an AI risk report to triage who truly needs a biopsy now, and who doesn’t.
Health impact, not just cost:
Reduce avoidable biopsies by 10–15% and you free $300–$460M annually, shorten queues, and accelerate care for the women who do need intervention, especially in community clinics and rural sites.
Let’s replace over-biopsy with first-pass clarity.
Investment
Collaboration
Partnership